[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinitis-pigmentosa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinitis-pigmentosa":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,41,116,146,171,199,225,247,319,346,371,396,417,440,466,493,515,542,558,578,602,636,656,678,700],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100484566","universal-rare-gene-study-a-registry-and-natural-history-study-of-retinal-dystrophies-associated-with-rare-disease-causing-genetic-variants-100484566",false,"NCT05589714","Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants","Uni-Rare","Inclusion Criteria: Participants must meet all the following inclusion criteria at the Registry\u002FScreening Visit to be eligible to enroll into the genetic screening phase:\n\n1. Willing to participate in the study and able to communicate consent during the consent process\n2. Willing and able to complete all applicable Registry\u002FScreening Visit assessments\n3. Age ≥ 4 years\n4. Must have a single gene on the RD Rare Gene List which meets one of the Genetic Screening Criteria below based on a genetic report\\* from a clinically certified lab (or from a research lab which has been approved by the study Genetics Committee):\n\nInheritance Pattern is Recessive and has at least 2 disease-causing variants which are homozygous or heterozygous in trans\n\nOR\n\nInheritance Pattern is Recessive and has 2 disease-causing variants with unknown phase and meets all the following additional informatic criteria that is consistent with likely segregation in trans:\n\n1. Investigator confirms genotype and phenotype are consistent with autosomal recessive inheritance\n2. The 2 disease-causing variants have not been reported in cis in variant databases\n3. No additional potentially pathogenic variants were found on the gene (and the sequencing data for the gene were sufficiently robust to detect any additional potentially pathogenic variants)\n4. No potentially pathogenic variants were found in other common, likely candidate genes for the proposed condition\n\nOR\n\nInheritance Pattern is Dominant, X-linked, or Mitochondrial and has at least 1 disease-causing variant\n\nBoth eyes must meet the following criteria at the Registry\u002FScreening Visit to enroll into the genetic screening phase:\n\n1. Both eyes must have a clinical diagnosis of retinal dystrophy\n2. Both eyes must permit good quality photographic imaging (e.g., but not limited to, clear ocular media, adequate pupil dilation, stable fixation)\n\nExclusion Criteria:\n\nParticipants must not meet any of the following exclusion criteria at the Registry\u002FScreening Visit to be eligible to enroll into the genetic screening phase:\n\n1\\. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy including amiodarone, chloroquine, deferoxamine, hydroxychloroquine, pentosan polysulfate, tamoxifen, and deferoxamine Note: Since this is an observational study, pregnant women will not be specifically excluded from participation. However, minors that are pregnant shall be precluded from participation until they become the age of majority.\n\nOcular Exclusion Criteria:\n\nIf either eye has any of the following ocular exclusion criteria at the Registry\u002FScreening Visit, then the participant is not eligible to enroll into the genetic screening phase:\n\n1. Current vitreous hemorrhage\n2. Current complications of pathological myopia (for example, but not limited to, myopic maculopathy including atrophy, scar, choroidal neovascularization, schisis) that could inhibit ability to obtain good quality photographic imaging\n3. History of intraocular surgery (for example, but not limited to, cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within 3 months of Registry\u002FScreening Visit\n4. Current or any history of confirmed diagnosis of glaucoma (for example, but not limited to, glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)\n5. Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy\n6. History or current evidence of ocular disease that, in the opinion of the Investigator, may confound assessment of visual function (for example, but not limited to, tractional or rhegmatogenous retinal detachment, any vitreoretinal surgery, retinal vascular occlusion, proliferative diabetic retinopathy)\n7. The following medications and treatments are prohibited as they can affect progression of retinitis pigmentosa (RP). The participant must not have received the following treatments:\n\n   Any use of ocular stem cell or gene therapy Any treatment with ocriplasmin Treatment with Ozurdex (dexamethasone), Iluvien, or Yutiq (fluocinolone acetonide) intravitreal implant\n8. The following medications and treatments are excluded within the specified timeframe:\n\nTreatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Registry\u002FScreening Visit date)\n\nTreatment with any other product within five times the expected half-life of the product (time from last treatment date to Registry\u002FScreening Visit date is at least 5 times the half-life of the given product)","ALL","4 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","This is an international, multicenter study with two components:\n\nRegistry\n\n* A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection\n* Enrollment is open to all genes on the RD Rare Gene List\n\nNatural History Study\n\n* A prospective, standardized, longitudinal Natural History Study\n* Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows.\n\nRegistry Objectives\n\n1. Genotype Characterization\n2. Cross-Sectional Phenotype Characterization (within gene)\n3. Establish a Link to My Retina Tracker Registry (MRTR)\n4. Ancillary Exploratory Studies - Pooling of Genes\n\nNatural History Study Objectives\n\n1. Natural History (within gene)\n2. Structure-Function Relationship (within gene)\n3. Risk Factors for Progression (within gene)\n4. Ancillary Exploratory Studies - Pooling of Genes",[25,26],"Inherited Retinal Degeneration","Retinitis Pigmentosa",[25],"RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":32},"2023-05-11",{"date":36,"type":21},"2030-12-15",{"name":38,"class":39},"Jaeb Center for Health Research","OTHER",36,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":74,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","18 Years",{"count":51,"type":21},500,"INTERVENTIONAL",[54],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[57,58,26,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73],"Retinal Disease","Age-Related Macular Degeneration","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[75,76,77,78,79,80,81,82,83,57,72,84,85,86,87,88,89,90,91,92,26,59,93,94,95,71,63,62,60,96,97,98,99,100,101,102,103,104,65,66,105,73],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":107,"type":32},"2026-06-29",{"date":109,"type":32},"2016-01",{"date":111,"type":21},"2028-07-31",{"name":113,"class":114},"MD Stem Cells","INDUSTRY",4,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":4,"leadSponsor":142,"locationsCount":145},"100165906","cell-collection-to-study-eye-diseases-100165906","NCT01432847","Cell Collection to Study Eye Diseases","Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls","* INCLUSION CRITERIA:\n\nTo be eligible, participants must meet the following inclusion criteria.\n\n1. Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or have a legally authorized representative if they are adults without consent capacity.\n2. Participant meets one of the following criteria:\n\n   1. Participant has been diagnosed with an ocular condition of interest including but not limited to: degenerative retinal diseases, optic atrophy, microphthalmia\u002Fanophthalmia, ciliopathy, and other ocular developmental or degenerative conditions.\n   2. Participant is free of eye diseases and could serve as an unaffected control. Participant's age, sex, and ethnicity must match an existing participant with one of the eye diseases under study. Control participants matched to AMD participants must not have drusen greater than 63 microns in size.\n3. Adult participant is able to provide a punch skin biopsy and 30 mL of peripheral venous blood OR child participant is able to provide a punch skin biopsy and the lesser of 5 mL\u002Fkg or 30 mL of peripheral venous blood. Healthy, unaffected children will only have one skin punch biopsy done 3mm or less in size. In affected participants, an additional punch may be gathered if the initial sample does not contain adequate cells. This will be taken from children ages seven years and older. Sampling of ten occipital hairs and\u002For saliva may be pursued at the investigator's discretion. Participants not able to provide a skin biopsy or blood sample may opt to provide 100-200 ml of fresh urine. As a rule, samples will be collected on non-sedated\u002Fanesthetized participants. Sedation\u002Fanesthesia will NOT be used solely for the purpose of sample collection. In rare instances where a minor requires sedation for another medically indicated procedure, samples may be collected at the time of sedation\u002Fanesthesia. Because young children may not be able to cooperate with sample collection, those unable to provide a skin biopsy, urine sample or a blood sample may be excluded from the study, based on the judgment of the examining investigator.\n4. Participant meets one of the following criteria:\n\n   1. Participant affected with an ocular condition is one year of age or older.\n   2. Participant affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n   3. Unaffected participant is seven years of age or older and willing and able to provide assent.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present.\n\n1. Participant is unable to comply with study procedures.\n2. Participant has a systemic disease that, in the opinion of the investigator, compromises the ability to provide adequate samples. Examples of co-existing diseases that would exclude a participant include a bleeding diathesis or a genetic susceptibility to infections, particularly cutaneous infections.\n\nADDITIONAL CRITERIA FOR CLNICAL-GRADE CELL LINE GENERATION:\n\nThe additional eligibility criteria must be met for participants donating samples for the generation of clinical-grade cell lines.\n\nInclusion Criteria\n\n1. Participant must be greater than 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment.\n2. Participant is able to provide a punch skin biopsy and 200 ml of peripheral venous blood.\n3. Participant is willing and eligible to co-enroll in NEI protocol 15-EI-0128.\n\nExclusion Criteria\n\n1. Participant has medical history that includes any of the following:\n\n   1. Thrombocytopenia or other blood dyscrasias\n   2. Bleeding diathesis\n   3. Antibiotic use within the prior 48 hours\n   4. Active cancer or history of cancer within the past five years\n   5. History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood\n\n      Banking and Transfusion Services, American Association of Blood Banks.\n   6. Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov\u002Ftravel)\n   7. At risk for the possible transmission of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, \"Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) by Blood and Blood Products\"\n2. Participant is currently febrile (temperature \\> 38 degrees C)\n3. Participant has Hemoglobin level:\n\n   * African American women \\\u003C11.5 grams\u002FdL\n   * Other women \\\u003C 12.0 grams\u002FdL\n   * Men \\\u003C12.5 grams\u002FdL\n4. Participant has low hematocrit (HCT):\n\n   * African American women \\\u003C 34%\n   * Other women \\\u003C36%\n   * Men \\\u003C38%\n5. Participant has Platelets \\\u003C150 x 103\u002FmicroL\n6. Participant has Absolute neutrophil count \\\u003C1.0 x 103\u002FmicroL.\n7. Participant has positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, American Association of Blood Banks. The currently required tests include anti-HIV1\u002F2, anti-HCV, anti-HBc, Anti-HTLV I\u002FII, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV, HBV, and HIV-1).",true,"1 Day","120 Years",{"count":127,"type":21},930,"Background:\n\n\\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect cells from people with Best disease, L-ORD, and AMD, and compare their cells with those of healthy volunteers.\n\nObjectives:\n\n\\- To collect hair, skin, saliva, urine, and\u002For blood samples to study three eye diseases that affect the retina: Best disease, L-ORD, and AMD.\n\nEligibility:\n\n* Individuals affected with ocular condition is one year of age or older.\n* Individuals affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n* Unaffected individuals are seven years of age or older.\n\nDesign:\n\n* The study requires one visit to the National Eye Institute.\n* Participants will be screened with a medical and eye disease history. They may also have an eye exam.\n* Participants will provide a hair sample, saliva sample, urine sample, blood sample, and\u002For a skin biopsy. The hair will be collected from the back of the head, and the skin will be collected from the inside of the upper arm.",[57,130,131,26],"AMD","Retinal Degeneration",[133,134,135,136,131,58,130],"Best Disease","Late-Onset Retinal Degeneration (L-ORD)","Age-Related Macular Degeneration (AMD)","Natural History","2026-06-18",{"date":139,"type":32},"2026-06-22",{"date":141,"type":32},"2011-09-07",{"name":143,"class":144},"National Eye Institute (NEI)","NIH",1,{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":52,"phases":155,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100564420","phase-2-a-phase-ii-study-of-intravitreal-kio-301-in-patients-with-late-stage-retinitis-pigmentosa-100564420","NCT06628947","A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa","A Phase II, Randomised, Controlled, Double Masked, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa","ABACUS-2","Inclusion Criteria:\n\n1. Be aged 18 years or older at the time of consent.\n2. Provide informed consent prior to any study procedures, as stipulated by local laws, Ethics Committee (EC) and Regulatory Authority (RA) guidelines.\n3. Be willing and able to follow all study instructions, attend all study visits, and complete all study assessments.\n4. Have a clinical diagnosis of non-syndromic RP, with the exception of Usher's Syndrome Type II (USH2) which is allowed.\n5. Have a visual acuity as per the Berkeley Rudimentary Vision Test (BRVT) at Screening of:\n\n   * NLP OU confirmed by inability to see pen torch light at 25 cm OD, OS, and OU (assigned logMAR of 4.0).\n   * LV OU limited to logMAR \\> 1.6 and \\\u003C 4.0.\n6. Other than intravitreal corticosteroids, participants must not receive intravitreal concomitant medications from Screening until end of study.\n7. For Low Vision (LV) OU participants only: must pass at least one multi-luminance functional vision (MLFV) test at two successive light levels (between 1 and 500 lux), or at 1400 lux. Additionally, they must fail the same test at 0.125 and 0.35 lux.\n8. Must agree to follow appropriate contraception requirements from Screening until 3 months after the last dose of IMP.\n\n   * Participants assigned female at birth who are of child-bearing potential (OCBP) must agree to a pregnancy test at Screening and use an acceptable method of birth control including oral, transdermal, injectable, or implantable hormonal contraception, intrauterine device, abstinence from intercourse with partner assigned male at birth, or surgical sterilisation of partner assigned male at birth. Participants assigned female at birth are not OCBP if they have had a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or are post-menopausal by at least 12 months.\n   * Participants assigned male at birth with a partner OCBP must be surgically sterile for at least 3 months prior to starting study drug, or ensure their partner uses contraception as outlined above, and must use a male condom. Participants assigned male at birth must not donate sperm from Screening until 3 months after the last dose of IMP.\n   * Participants who have practiced true abstinence for at least 1 year due to usual and preferred lifestyle choice are exempt from contraceptive requirements. If a participant who is abstinent becomes sexually active, they must agree to use appropriate contraception as described above.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding, or plan to become pregnant during the study.\n2. Have, in the investigator's opinion, evidence of material\u002Fsubstantial optic nerve disease.\n3. Have a history of one or more retinal detachments.\n4. Other than RP related macular pathologies, have in the investigator's opinion, clinically significant ocular disease (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca), or clinically significant opacities of the media which might interfere with the study assessments, or the ability of the participant to complete the study.\n5. Have a history of high myopia (\\> 6 diopters).\n6. Have uncontrolled severe glaucoma defined as intraocular pressure (IOP) of \\> 26 mmHg when on 2 or more IOP lowering medications and cup disc ratio of ≥ 0.8, as diagnosed by an ophthalmologist.\n7. Have had a previous intraocular surgery (with the exception of phacoemulsification cataract surgery and YAG capsulotomy more than 12 months prior to first study drug administration, which is allowed).\n8. Have aphakia or a subluxed intraocular lens, or have evidence of zonular weakness that in the opinion of the investigator would result in light obfuscation.\n9. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within five years prior to screening, a history of suicide plan.\n10. Have any clinically significant abnormality at screening determined by medical history, vital signs, clinical biochemistry, haematology, urinalysis, or a 12-lead electrocardiogram (ECG), as assessed by the investigator, which might interfere with the study assessments or the ability of the participant to complete the study.\n11. Have any other medical condition or significant co-morbidities, or any finding during screening, which in the view of the Investigator is likely to interfere with the study or put the Participant at risk, confound study data, or interfere significantly with study participation.\n12. Have clinical signs of active ocular or systemic infection and\u002For a temperature greater than 38.0°C at the time of screening. Study entry must be deferred at least 14 days from resolution.\n13. Have participated in any investigational study within 30 days prior to screening, prior exposure to an investigational product within 5 elimination half-lives, or planned used of an investigational product or device during the study.\n14. Have known or suspected hypersensitivity to any of the study drug excipients.\n15. Are taking any medications that are known to be toxic to the retina or optic nerve.",{"count":40,"type":21},[156],"PHASE2","The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP).\n\nLate-stage RP patients will include those patients with No Light Perception (NLP), or Low Vision (LV).",[26],[160,161],"Late-stage RP with No Light Perception","Late-stage RP with Low Vision","2026-06-16",{"date":137,"type":32},{"date":165,"type":32},"2025-08-29",{"date":167,"type":21},"2027-08",{"name":169,"class":114},"Kiora Pharmaceuticals, Inc.",5,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":52,"phases":181,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":145},"100589317","phase-1-safety-and-efficacy-of-zvs203e-in-the-treatment-of-retinitis-pigmentosa-caused-by-rho-gene-mutation-100589317","NCT06952842","Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation","A Single-Arm, Open-Label, Phase 1\u002F2 Clinical Trial of ZVS203e in Subjects With Retinitis Pigmentosa Associated With RHO Mutation","ZVS203e","Inclusion Criteria:\n\n1. Patients with a clinical diagnosis of retinitis pigmentosa (RP) (aged 18 years or older);\n2. RHO (c.403C\\>T, p.R135W) gene site-specific mutation was confirmed by genetic testing, and no other ophthalmic genetic diseases were complicated;\n3. The researchers judged that the target eye had viable retinal photoreceptor cells and retinal pigment epithelial cells;\n4. The best corrected visual acuity of the target eye is between 2.0 LogMAR and 0.5 LogMAR (including 2.0 LogMAR and 0.5 LogMAR, which is equivalent to a number of fingers to 60 letters);\n5. The subject and his or her spouse agree to use effective contraception during the trial period and for at least 1 year after dosing;\n6. Voluntarily participate in clinical trials and sign informed consent, and can complete the whole test process according to the protocol requirements.\n\nExclusion Criteria:\n\n1. The researcher determined that the target eye currently has or had macular lesions such as macular hiatal hole or macular neovascularization;\n2. Have other eye conditions that may prevent surgery or interfere with interpretation of the study endpoint, such as glaucoma, diabetic retinopathy, eye or periocular infections, active endophthalmitis, etc.\n3. Within 3 months prior to enrollment, the study eye had received any intraocular surgery, such as phacoemulsification cataract extraction.\n4. The study eye had undergone retinal reattachment or vitrectomy.\n5. Participants who had participated in any drug or medical device clinical trial within 3 months before enrollment;\n6. Previously treatment of either eye with gene therapy or stem cell therapy for RP and other ocular diseases, including but not limited to viral vector gene therapy, RNA therapy.\n7. Treatment with medications that may affect the efficacy and safety evaluation of the investigational product within 3 months prior to enrollment (e.g., ranibizumab, bevacizumab, aflibercept, conbercept).\n8. Known allergy to the drug planned to be used in the study.",{"count":180,"type":21},18,[182,156],"PHASE1","This trial employs a single-arm, open-label seamless Phase I\u002FII design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.",[26],[186,177,187,188],"Gene editing","RHO","Retinitis pigmentosa","2026-06-15",{"date":191,"type":32},"2026-06-17",{"date":193,"type":32},"2025-08-04",{"date":195,"type":21},"2045-06-18",{"name":197,"class":198},"Chigenovo Co., Ltd","NETWORK",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":123,"sex":17,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":145},"100076799","retinal-imaging-in-patients-with-inherited-retinal-degenerations-100076799","NCT00254605","Retinal Imaging in Patients With Inherited Retinal Degenerations","High Resolution Retinal Imaging in Patients With Inherited Retinal Degenerations","Inclusion Criteria:\n\n* Subjects must speak and understand English\n* Subjects must have pupils that dilate to at least 6 millimeters diameter.\n* Subjects must be willing to travel to University of California (UC) Berkeley.\n* Subjects are financially responsible for their travel to the San Francisco area if they are not San Francisco residents.\n\nExclusion Criteria:\n\n* Cataract\n* Irregular corneal astigmatism (keratoconus)\n* Prior refractive surgery","13 Years",{"count":208,"type":21},400,"The purpose of this study is to determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal degenerations using the Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO).",[26],[212,213,214,215],"imaging","adaptive optics scanning laser ophthalmoscope","optical coherence tomography","electroretinography","2026-06-03",{"date":218,"type":32},"2026-06-05",{"date":220,"type":32},"2005-11-01",{"date":222,"type":21},"2028-11-01",{"name":224,"class":39},"University of California, San Francisco",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":123,"sex":17,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":145},"100256498","rod-and-cone-mediated-function-in-retinal-disease-100256498","NCT02617966","Rod and Cone Mediated Function in Retinal Disease","* INCLUSION CRITERIA:\n* Participant must be five years of age or older.\n* Participant (or legal guardian) must understand and sign the protocol s informed consent document.\n* Participant must be able to cooperate with the testing required for this study.\n\nFor Participants with retinal disease only:\n\n* Participant must have retinal disease, defined as evidence of loss of retinal dysfunction and\u002For degeneration as established by standard clinical methods including perimetry, ERG and imaging.\n* Participant must have a measurable visual acuity.\n\nFor Healthy Volunteers only:\n\n-Participant must have visual acuity of 20\u002F20 or better, with or without correction (e.g., glasses or contact lens) in at least one eye.\n\nEXCLUSION CRITERIA:\n\n-Participant with changes in pre-retinal media sufficient to obscure a view of the retina.","5 Years","100 Years",{"count":51,"type":21},"Background:\n\nRetinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.\n\nObjectives:\n\nTo find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track its changes.\n\nEligibility:\n\nPeople ages 5 and older with:\n\nRetinal disease OR\n\n20\u002F20 vision or better with or without correction in at least one eye\n\nDesign:\n\nParticipants will be screened with medical and eye history and eye exam. Those with retinal disease will also have:\n\nEye imaging: Drops dilate the eye and pictures are taken of it.\n\nVisual field testing: Participants look into a bowl and press a button when they see light.\n\nElectroretinogram (ERG): An electrode is taped to the forehead. Participants sit in the\n\ndark with their eyes patched for 30 minutes. Then they get numbing drops and contact\n\nlenses. Participants watch lights while retina signals are recorded.\n\nVisit 1 will be 3-8 hours. Participants will have up to 6 more visits over 6-12 months. Visits include:\n\nEye exam and imaging\n\nTime course of dark adaptation: Participants view a background light for 5 minutes then\n\npush a button when they see colored light.\n\nDark adapted sensitivity: Participants sit in the dark for 45 minutes. They push a button when\n\nthey see colored light.\n\nFor participants with retinal disease, ERG and visual field testing",[131,26,236],"Stargardt's Disease",[83,131,26,236,238],"Dark Adaptation","2026-05-28",{"date":241,"type":32},"2026-05-29",{"date":243,"type":32},"2016-03-24",{"date":245,"type":21},"2029-12-30",{"name":143,"class":144},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":123,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":255,"targetDuration":257,"studyType":22,"phases":4,"briefSummary":258,"conditions":259,"keywords":281,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":145},"100242565","inherited-retinal-degenerative-disease-registry-100242565","NCT02435940","Inherited Retinal Degenerative Disease Registry","Foundation Fighting Blindness My Retina Tracker Registry","MRTR","Inclusion Criteria:\n\n* Diagnosed with an inherited retinal degenerative disease OR\n\nExclusion Criteria:\n\n* Glaucoma only\n* Diabetic retinopathy only\n* Non-retinal disease\n* Not heritable retinal disease",{"count":256,"type":21},20000,"20 Years","The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.",[260,57,261,262,263,264,133,265,266,93,95,267,268,269,270,271,272,273,274,275,26,276,277,94,278,279,59,280],"Eye Diseases Hereditary","Achromatopsia","Bardet-Biedl Syndrome","Bassen-Kornzweig Syndrome","Batten Disease","Choroidal Dystrophy","Choroideremia","Congenital Stationary Night Blindness","Enhanced S-Cone Syndrome","Fundus Albipunctatus","Goldmann-Favre Syndrome","Gyrate Atrophy","Juvenile Macular Degeneration","Kearns-Sayre Syndrome","Leber Congenital Amaurosis","Refsum Syndrome","Retinitis Punctata Albescens","Retinoschisis","Rod Dystrophy","Rod Monochromacy","Usher Syndrome",[282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309],"inherited retinal degenerative disease","retinitis pigmentosa","Usher","Leber","Bardet-Biedl","Batten","Best","cone dystrophy","cone-rod dystrophy","choroideremia","congenital night blindness","enhanced s-cone","cone monochromacy","Goldmann-Favre","Kearns-Sayre","Refsum","retinoschisis","rod-cone dystrophy","rod dystrophy","rod monochromacy","Sorsby pseudoinflammatory dystrophy","stargardt","achromatopsia","juvenile inherited macular degeneration","cone dichromacy","cone trichromacy","Charcot-Marie-Tooth","albipunctate dystrophy","2026-05-18",{"date":312,"type":32},"2026-05-19",{"date":314,"type":4},"2014-06",{"date":316,"type":21},"2037-06",{"name":318,"class":39},"Foundation Fighting Blindness",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":325,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":345},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567","NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","21 Years",{"count":327,"type":21},100,"The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[131,58,26,330,331,332,93,333,334,278],"Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Rod Dystrophy","Rod Cone Dystrophy","2026-05-06",{"date":337,"type":32},"2026-05-08",{"date":339,"type":32},"2021-08-27",{"date":341,"type":21},"2028-09-30",{"name":343,"class":344},"Food and Drug Administration (FDA)","FED",2,{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":123,"sex":17,"minAge":353,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":145},"100198971","high-resolution-retinal-imaging-100198971","NCT01866371","High Resolution Retinal Imaging","AOSLO","Inclusion Criteria:\n\n* Males or females age 7 years or older.\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent. Child subjects age 7-17 must give assent.\n* Reasonable compliance with an imaging protocol as determined by the study personnel.\n\nExclusion Criteria:\n\n* Individuals that are at risk to acute glaucoma.\n* Individuals that are photophobic and experience adverse psychological reactions to flashes of light.\n* Ocular opacities, high refractive error, and high frequency of nystagmus as determined by the study team.","7 Years",{"count":355,"type":21},600,"Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease. This protocol uses an adaptive optics scanning laser ophthalmoscope (AOSLO) to image the normal and diseased retina with individual cellular resolution non-invasively. The primary objective of this study is to obtain and analyze high-resolution images of the retina, in particular by imaging the cone photoreceptor mosaic, the retinal vasculature and other retinal layers. The study design will involve case-control studies, where cases are followed over time. Subjects age 7 and older may be invited to participate. The main research procedure involves retinal imaging with the AOSLO. The primary endpoint is the observation of differences in retinal images between subjects with and without retinal diseases. These changes will be quantified by examining the cell density, size, spacing and regularity of the cone photoreceptor mosaic, as well as examining the differences between other retinal layers.",[358,26,359,266,86],"Stargardts","Age-related Macular Degeneration",[83,212,361],"retinal degeneration","2026-04-28",{"date":364,"type":32},"2026-05-05",{"date":366,"type":4},"2013-05",{"date":368,"type":21},"2031-12",{"name":370,"class":39},"University of Pennsylvania",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":379,"maxAge":232,"enrollmentInfo":380,"targetDuration":231,"studyType":22,"phases":4,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":145},"100610531","natural-history-study-of-patients-with-eys-associated-rp-100610531","NCT07228793","Natural History Study of Patients With EYS-Associated RP","Natural History Prospective Open Clinical and Genetic Study of Patients With EYS-Associated Retinitis Pigmentosa","RUS_EYS","Inclusion Criteria:\n\n1. Willing to participate in the study and able to communicate consent during the consent process\n2. Ability to return for all study visits over 48 months\n3. Age ≥ 18 years\n4. Must meet one of the Genetic Screening Criteria, defined below:\n\nScreening Group A: At least 2 disease-causing variants in the EYS gene which are homozygous or heterozygous in trans, based on a report from a clinically-certified lab (or a report from a research lab that has been pre-approved by the Study Committee) Screening Group B: Only 1 disease-causing variant in the EYS gene, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Screening Group C: At least 2 disease-causing variants in the EYS gene which are unknown phase, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he\u002Fshe would still qualify as long as there is at least 1 disease-causing variant(s) on the EYS gene.\n\nOcular Inclusion Criteria:\n\nBoth eyes must meet all of the following:\n\n1. Clinical diagnosis of retinal dystrophy\n2. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging\n\nExclusion Criteria:\n\n1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP\u002Fretinal dystrophy genes other than EYS.\n2. Expected to enter experimental treatment trial at any time during this study\n3. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)\n\nOcular exclusion Criteria:\n\nIf either eye has any of the following, the participant is not eligible:\n\n* Current vitreous hemorrhage\n* Current or any history of rhegmatogenous retinal detachment\n* Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia\n* History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months\n* Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous visual functions changes or nerve changes, or history of glaucoma filtering surgery)\n* Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy\n* History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function\n* History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:\n* Any use of ocular stem cell or gene therapy\n* Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)\n* Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)","14 Years",{"count":381,"type":21},45,"This natural history study of patients with EYS mutations from Russia and former CIS (Commonwealth of Independent States) territories will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to EYS mutations. This approach helps to develop experimental treatment protocol, and assessing its effectiveness.\n\nThe goals and expected impact of this natural history study are to:\n\n1. Describe the natural history of retinal degeneration in patients with biallelic mutations in EYS gene in Russia and former CIS territories.\n2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials in EYS-related retinal degeneration in Russia and former CIS territories.\n3. Identify well-defined subpopulations for future clinical trials of investigative treatments for EYS-related retinal degeneration in Russia and former CIS territories.",[26,384],"Eye Diseases",[386,387,188],"EYS mutation","RP","2026-04-22",{"date":362,"type":32},{"date":391,"type":32},"2025-11-07",{"date":393,"type":21},"2030-03-30",{"name":395,"class":114},"Sensor Technology for Deafblind",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":52,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":345},"100584633","phase-1-a-study-to-investigate-the-safety-of-dsp-3077-after-a-unilateral-eye-injection-in-male-and-female-participants-18-years-of-age-or-older-with-retinitis-pigmentosa-100584633","NCT06891885","A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa","A Prospective, Open-label, Single-arm, Dose-escalation Study of the Safety and Tolerability of a Single Subretinal Uniocular Injection of Allogeneic Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Sheets (DSP-3077) in Adults With Retinitis Pigmentosa (RP)","Inclusion Criteria:\n\n* Participant is \\>= 18 years of age at the time of signing the informed consent.\n* Participant has a clinical diagnosis of nonsyndromic retinitis pigmentosa.\n* Participant is willing to consent to genetic testing, if not already done.\n* Cohorts 1 and 2: Participant will have BCVA in the study eye between hand motion and 20 ETDRS letter score (approximately \\\u003C= 20\u002F400 Snellen equivalent), inclusive at Screening and Baseline.\n* Cohort 3: Participant will have BCVA in the study eye between 20 ETDRS letter score (approximately \\>= 20\u002F400 Snellen equivalent) and 35 ETDRS letter score (approximately \\\u003C= 20\u002F200 Snellen equivalent), inclusive at Screening.\n* Participant is in good physical health, based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests at Screening.\n\nExclusion Criteria:\n\n* Participant has an eye disease or visual disorder other than RP that impairs visual function (eg, retinal vascular disease, glaucoma).\n* Participant has any other eye condition (eg, ocular media opacity, nystagmus), which in the opinion of the investigator, would preclude an accurate evaluation at any time during the study and\u002For make surgical delivery more challenging.\n* Participant has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the investigator, would limit the participant's ability to complete and\u002For participate in the study.\n* Female participant who is pregnant or lactating or planning to become pregnant.\n* Participant has received treatment with any nonapproved, experimental, or investigational therapy in either eye (systemic, topical, intravitreal) and\u002For received treatment in an interventional clinical trial for an eye disease or disorder within 90 days or 5 half-lives, whichever is longer, prior to Screening.\n* Participant has previously received cell therapy, gene augmentation therapy, genome editing therapy, or any subretinal administered therapy for an eye disease or disorder.",{"count":404,"type":21},12,[182,156],"The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.",[26],"2026-04-14",{"date":410,"type":32},"2026-04-17",{"date":412,"type":21},"2026-04-16",{"date":414,"type":21},"2032-10-31",{"name":416,"class":114},"Sumitomo Pharma America, Inc.",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":52,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":439},"100586227","phase-2-safety-of-a-single-intravitreal-injection-of-60m-jcell-famzeretcel-in-retinitis-pigmentosa-rp-100586227","NCT06912633","Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)","A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)","Inclusion Criteria:\n\n1. Clinical diagnosis of RP supported by at least 2 of the following clinical findings: (1) Loss of peripheral vision on formal visual field testing, (2) Symptoms of night blindness or difficulty adjusting to dim light, or (3) Optical coherence tomography (OCT) outer retinal atrophy consistent with RP.\n2. Electroretinography (ERG) results that support diagnosis of RP including nondetectable or severely reduced rod responses (defined as less than 30% of the lower limit of normative values for the ERG lab performing the test), with prolonged implicit time OU (i.e., ensure bilateral involvement) and greater rod than cone loss. If genotyping results from a certified genetic testing lab document mutations clearly diagnostic of RP, with no other potential diagnosis of a disease(s) distinct from RP, the genetic test may be used in lieu of an ERG.\n3. Subject age ≥ 18 years and ≤ 60 years at time of signing of consent.\n4. Interocular BCVA disparity ≤ 15 letters.\n5. Central subfield thickness (CST) ≥ 130 µm in the study eye.\n6. BCVA no better than 55 letters and no worse than 1 letter using the Early Treatment Diabetic Retinopathy Study (ETDRS) testing protocol in the study eye.\n7. Ability to reliably fixate with the study eye at least 75% of the time as indicated by a fixation score of four (4) or five (5) on semi-automated kinetic visual fields.\n8. Ability to record at least two reliable trials at a minimum baseline contrast sensitivity reading of 1.28 at a minimum of one spatial frequency using the Beethoven system in the study eye.\n9. Central island visual field area (central island contiguous to fixation), of ≥ 50.3 deg2 (\\~ central island visual field diameter ≥ 8°) in the study eye.\n10. Willingness of subject to provide informed consent, including acknowledgement that they are able and willing to attend all required study visits, follow study protocol assessment instructions, travel by air if necessary, and provide Health Insurance Portability and Accountability Act (HIPAA) authorization.\n11. Willingness of subject to provide a blood sample for human leukocyte antigen (HLA) typing, if not done previously with available results.\n12. Willingness of subject to consent to testing for RP gene mutation typing, if not performed previously with available results.\n13. Adequate organ function.\n14. Negative active infectious disease screen (active infection with Hepatitis B, C, human immunodeficiency virus \\[HIV\\]).\n15. A female subject of childbearing potential must have a negative pregnancy test (urine human chorionic gonadotropin) at entry (prior to treatment).\n16. Women of childbearing potential must agree to use a medically accepted method of contraception for at least 12 months after jCell injection.\n17. For male patients whose partners are of child-bearing potential, willingness to use a medically accepted method of contraception.\n\nExclusion Criteria:\n\n1. Participation in any clinical trial of a drug intervention within the last 6 months, with the exception of a N-acetyl cysteine (NAC) study.\n2. History of ocular treatment with any non-approved, experimental, investigational or neuroprotectant therapy (systemic, topical, intravitreal) or device in either eye, including previous jCyte clinical trials. Individuals with a history of NAC treatment may take part in the study following a 7-day washout period (prior to Baseline testing).\n3. Subject is currently breast feeding\u002Fpumping or is planning to breast feed\u002Fpump during the 12 months after study treatment.\n4. Subject is pregnant or intends to become pregnant less than 12 months after jCell injection.\n5. Known allergy to gentamicin.\n6. History of adverse reaction to dimethyl sulfoxide (DMSO).\n7. Prior ocular treatment with corticosteroids (systemic, periocular, intracanalicular or intravitreal - in either eye) within six months of study randomization or the anticipated need for the use of these agents to treat a pre-existing ocular condition.\n8. Clinical evidence of history of any eye disease or pathology, other than RP, IN EITHER EYE, that is associated with increased risk of pathology developing in the study eye, that could impair visual function, testing procedures, clinical trial endpoint measurements and\u002For the outcome of the study. Examples include central serous retinopathy, vitreomacular traction, pattern\u002Fvitelliform dystrophy\n9. Clinical evidence of history of any eye disease or pathology, other than RP, IN THE STUDY EYE, that could potentially impair visual function, testing procedures, clinical trial endpoint measurements and\u002For the outcome of the study.\n10. Concurrent use of any prohibited therapies.\n11. History of prior use of the following medications is prohibited if any retinal\u002Fretinal pigment epithelium (RPE) abnormalities are noted in the macula on exam or OCT: Hydroxychloroquine or chloroquine (Plaquenil); Pentosan polysulfate sodium \\[PPS\\] (Elmiron); and Interferon (Intron A, Roferon-A, IFN-alpha, alpha interferon).\n12. Any mental health issue likely to prevent subject from reliably performing study testing and\u002For examinations including dementia, schizophrenia, bipolar disorders if not reliably controlled on medications, depression if any history of hospitalization or in-patient treatment or if not sufficiently controlled on medications to enable, in the opinion of the investigator, travel to and compliance with study testing requirements over the study period.\n13. Uncontrolled blood pressure defined as systolic pressure \\> 180mmHg and\u002For diastolic blood pressure \\> 110mmHg, while subject is at rest.\n14. Any chronic systemic disease requiring continuous treatment with systemic steroids or immunosuppressive agents.\n15. History of any disease interfering with the participation in the study according to the investigator judgment, including of any type of cancer that is not in remission or considered cured, diabetes mellitus (history of gestational diabetes is acceptable), renal failure, stroke, transient ischemic attack (TIA), any systemic immune condition, any coagulopathy disorder that is not adequately managed\u002Fcontrolled.\n16. Current systemic treatment for a confirmed active infection.\n17. For male patients whose co-partners are of child-bearing potential, lack of willingness to use a medically accepted method of contraception, not including the rhythm method, for at least 12 months after jCell injection.","60 Years",{"count":426,"type":21},60,[156],"This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.",[26],"2026-04-08",{"date":432,"type":32},"2026-04-13",{"date":434,"type":32},"2025-06-20",{"date":436,"type":21},"2026-09",{"name":438,"class":114},"jCyte, Inc",14,{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":52,"phases":449,"briefSummary":450,"conditions":451,"keywords":452,"overallStatus":455,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":145},"100632095","phase-1-9-cis-beta-carotene-rich-extract-of-dunaliella-alga-in-retinitis-pigmentosa-patients-100632095","NCT07509229","9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients","Treatment With 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients - a Randomized Crossover Double Masked Study","Inclusion Criteria:\n\n1. Written informed consent to participate in the study\n2. Men or women aged 18 years or older\n3. Electroretinogram (ERG) responses compatible with the diagnosis of retinitis pigmentosa\n4. Positive for mutation(s) in retinoid cycle related genes\n\nExclusion Criteria:\n\n1. Currently a smoker\n2. Current use of vitamin A\u002F β-carotene supplements\n3. Known mutations in the ABCA4 gene\n4. Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery\n5. History of malignancy, excepting basal or squamous cell skin carcinoma\n6. Women who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception\n7. Uncontrolled hypertension, defined either as resting diastolic blood pressure \\>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \\>180 mmHg\n8. History of alcohol abuse or drug abuse or both\n9. Intention to engage in vigorous exercise or an aggressive diet regimen\n10. Uncontrolled endocrine or metabolic disease\n11. Participation in another investigational drug study within 4 weeks prior to enrolment\n12. Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study\n13. Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment",{"count":448,"type":21},41,[182,156],"The goal of this clinical trial is to learn if a natural supplement called 9-cis beta-carotene (derived from the Dunaliella alga) can improve vision and retinal function in adults with Retinitis Pigmentosa. The study will also monitor the safety of the food supplement and how it affects levels of Vitamin A-related proteins in the blood. The main questions the study aims to answer are: (1) Does taking the supplement improve light sensitivity in the retina (measured by microperimetry)? (2) Does the supplement improve electrical responses in the eye (ERG) or other visual functions like contrast and color vision? (3) How do blood levels of beta-carotene and Vitamin A change during treatment? Researchers will use a crossover design. This means every participant will receive both the active supplement and a placebo (a \"dummy\" pill with corn oil) at different times during the study to compare the results. Participants will take two soft-gel capsules twice a day for 3 months, undergo a 6-month \"washout\" period where no study capsules are taken.Then they will take the opposite capsules (either the supplement or the placebo) for another 3 months. The participants will visit the clinic 4 times over the course of 12 months for eye exams, eye imaging (like OCT), and blood tests. Participants will also receive follow-up phone calls every 6 weeks to check on their progress and health.",[26],[283,453,454],"retinoid cycle","beta carotene","NOT_YET_RECRUITING","2026-03-28",{"date":458,"type":32},"2026-04-03",{"date":460,"type":21},"2026-05-01",{"date":462,"type":21},"2029-04-30",{"name":464,"class":465},"Sheba Medical Center","OTHER_GOV",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":474,"enrollmentInfo":475,"targetDuration":4,"studyType":52,"phases":476,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":145},"100538577","early-phase-1-safety-and-efficacy-study-of-novel-gene-therapy-zm-02-for-retinitis-pigmentosa-patients-100538577","NCT06292650","Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients","Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-02 in Retinitis Pigmentosa","MOON","Inclusion Criteria:\n\nPatients who meet all of the following criteria can be selected as subjects:\n\n1. Clinically diagnosed with retinal pigment degeneration\n2. The visual acuity of study eye is no better than the finger counting, while the visual acuity of the study eye is not better than that of the contralateral eye\n3. The subject has had visual experience above the finger counting\n4. In the OCT examination of the tested eye, the disappearance of the ellipsoid zone is observed, but the inner nuclear layer and the nerve fiber layer of the retina are still present\n5. The refractive power of the tested eye is between -6.00 D and +6.00 D\n6. Not infected with the Human Immunodeficiency Virus (HIV) and other acute and chronic infectious diseases\n7. Voluntarily sign an Informed Consent Form (ICF), and the age is not less than 18 years and not more than 65 years\n8. Able to fully understand and agree to cooperate with the implementation of the research protocol\n\nExclusion Criteria:\n\nSubjects who meet any one of the following exclusion criteria will be excluded from the study:\n\n1. Pregnant women, breastfeeding women, or male and female subjects who do not agree to contraception during the 12 months before and after medication\n2. Subjects with narrow anterior chamber angles or any other medical conditions that contraindicate pupil dilation\n3. Subjects allergic to corticosteroids, who are unable to tolerate the corticosteroid treatment described in the protocol, or have active 4. concurrent infections that contraindicate treatment\n4. Subjects with systemic diseases, or other medical or mental illnesses, or other safety concerns for the study\n5. Subjects with other symptoms and\u002For diseases or conditions that can alter visual function, including but not limited to glaucoma and central nervous system lesions (mild cataracts are not included in this restriction)\n6. Eye diseases that may interfere with the assessment of vision during the study and\u002For interfere with other ocular assessments such as OCT\n7. Diseases that may affect the clinical trial, such as tumors, metabolic, immune-related diseases, etc.\n8. Subjects who have undergone major eye surgery within the last 3 months before screening\n9. Subjects with a history of malignant tumors within the last 5 years\n10. Subjects with other retinal diseases not suitable for this study, such as retinal detachment\n11. Patients undergoing or potentially undergoing immunosuppressive treatment for other diseases, excluding this study\n12. Participation in any clinical trials other than this study within the last 3 months\n13. Subjects who have received gene therapy outside of this study\n14. Other reasons deemed by the researcher as unsuitable for participation in this study","65 Years",{"count":404,"type":21},[477],"EARLY_PHASE1","This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.",[26],[481,482,387,483],"gene therapy","AAV","optogenetics","2026-03-25",{"date":486,"type":32},"2026-03-31",{"date":488,"type":32},"2024-02-25",{"date":490,"type":21},"2028-12-25",{"name":492,"class":114},"Zhongmou Therapeutics",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":145},"100631590","development-and-evaluation-of-functional-visual-field-and-navigation-endpoints-in-moderate-to-profound-inherited-retinal-disease-define-ird-100631590","NCT07502664","Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)","DEFINE-IRD","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F200 to HM in at least one eye.\n* Reasonably fluent in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient",{"count":7,"type":21},"The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[26,503,59,504,505,506],"Stargardt Macular Dystrophy","Geographic Atrophy From Age-related Macular Degeneration","X-linked Retinoschisis","Retinal Dystrophies","2026-03-24",{"date":486,"type":32},{"date":510,"type":32},"2026-02-19",{"date":512,"type":21},"2027-02",{"name":514,"class":114},"Ray Therapeutics, Inc.",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":474,"enrollmentInfo":522,"targetDuration":4,"studyType":52,"phases":524,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":455,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":145},"100509135","phase-2-role-of-uc-msc-and-cm-to-inhibit-vision-loss-in-retinitis-pigmentosa-phase-iii-100509135","NCT05909488","Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I\u002FII","Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I\u002FII","Inclusion Criteria:\n\n* Visus more than 20\u002F100\n* Have more than 0.68 uV on conical receptor cell amplitude checked by ERG\n* Visual field equivalent diameter more than 10o\n* Willing to sign informed consent as research subjects\n* Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue\n* Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations, and fill out a quality of life questionnaire\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Positive result of HIV test\n* Have a history of eye tumors\n* Under immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells\n* Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma\n* Do not come to control according to the schedule determined by the researcher (loss to follow up)",{"count":523,"type":21},30,[156,525],"PHASE3","The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.",[26],[529,530,531,532],"Allogeneic Mesenchymal Stem Cell","Umbilical Cord Mesenchymal Stem Cell","Conditioned Medium","Allogeneic Umbilical Cord Mesenchymal Stem Cell","2026-02-23",{"date":535,"type":32},"2026-02-25",{"date":537,"type":21},"2026-05",{"date":539,"type":21},"2027-09",{"name":541,"class":114},"PT. Prodia Stem Cell Indonesia",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":474,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":455,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":557,"locationsCount":345},"100499671","long-term-safety-of-uc-msc-transplantation-in-patients-with-retinitis-pigmentosa-100499671","NCT05786287","Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa","Long-term Safety of Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Transplantation in Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Visual field defects at the initial examination with Humphrey perimetry are between 25% to 50%\n* Willing to sign informed consent as research subjects\n* Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue\n* Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations and fill out a quality of life questionnaire\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Positive result of HIV test\n* Have a history of eye tumours\n* In the immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells\n* Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma\n* Do not come to control according to the schedule determined by the researcher (loss to follow up)",{"count":180,"type":21},"The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and\u002For CM transplantation.",[26],[529,530,531,532,553],"Safety",{"date":535,"type":32},{"date":537,"type":21},{"date":539,"type":21},{"name":541,"class":114},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":52,"phases":567,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":145},"100383858","phase-1-bs01-in-patients-with-retinitis-pigmentosa-100383858","NCT04278131","BS01 in Patients With Retinitis Pigmentosa","Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Confirmed diagnosis of retinitis pigmentosa\n* At least one eye with vision no better than 20\u002F160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.\n\nExclusion Criteria:\n\n* Prior receipt of any AAV gene therapy product\n* Large amplitude nystagmus",{"count":566,"type":21},20,[182,156],"A Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa",[26],"2026-01-21",{"date":572,"type":32},"2026-01-23",{"date":574,"type":32},"2020-02-06",{"date":245,"type":21},{"name":577,"class":114},"Bionic Sight LLC",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":52,"phases":586,"briefSummary":587,"conditions":588,"keywords":590,"overallStatus":455,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":4},"100509500","non-invasive-ultrasound-retinal-stimulation-for-vision-restoration-100509500","NCT05914233","Non-invasive Ultrasound Retinal Stimulation for Vision Restoration","Revolutionary Non-Invasive Ultrasound Technology for Vision Restoration in Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) Patients","Inclusion Criteria:\n\n1. Diagnosis of AMD (regardless of stage and type) or RP. At least two volunteers should diagnose with RP.\n2. Age 18 years or older\n3. No other eye-related health conditions\n4. No allergic history to commercial ultrasound gel\n5. Must be willing and able to comply with the protocol testing\n\nExclusion Criteria:\n\n1. Declining to participate and inability to give informed consent.\n2. Unable to comply with the process of the research\n3. If the volunteer has optic nerve disease, including the history of glaucoma, optic neuropathy, or other confirmed damage to optic nerve or visual cortex damage\n4. Unable to fixate that hinders obtaining high-quality imaging\n5. High myopia; refractive error of six diopters and above\n6. Pregnancy\n7. Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up, or testing of this study",{"count":170,"type":21},[54],"This clinical trial aims to test the safety and feasibility of using a non-invasive ultrasound device to stimulate retinal nerve cells and restore vision in patients with age-related macular degeneration. Previous studies have shown that artificial stimulation, such as electric and optic stimulations, can partially restore vision, but these methods are invasive and pose surgical risks. The study aims to develop a non-invasive method for retinal stimulation. The investigators will follow the FDA guidelines to limit the ultrasound power and adhere to all clinical trial regulations to ensure all participants' safety.\n\nThe main questions the investigators aim to answer are:\n\n* Is using high-frequency ultrasound safe using a wearable device for localized retinal neural activity stimulation?\n* Does the stimulation through the device restore vision in patients with age-related macular degeneration?\n\nParticipants in this study will be asked to undergo Optical Coherence Tomography (OCT) scanning before and after the ultrasound stimulation to evaluate the device's safety. Then, they will receive five stimulation-rest cycles and complete a questionnaire to report what they see and how they feel during the device's operation.",[58,26,589],"Ultrasound Therapy; Complications",[591,592,188,58],"Ultrasound Stimulation","Retinal","2026-01-06",{"date":595,"type":32},"2026-01-08",{"date":597,"type":21},"2027-01-10",{"date":599,"type":21},"2028-07-15",{"name":601,"class":39},"University of Southern California",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":123,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":52,"phases":612,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":145},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",{"count":611,"type":21},1200,[54],"Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[26,615,616,617,618,131,64,619,620,621,622,623,624,625,626],"Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Detachment","Vascular Inflammation","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":629,"type":32},"2025-11-18",{"date":631,"type":32},"2019-07-03",{"date":633,"type":21},"2027-07",{"name":635,"class":39},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":643,"maxAge":49,"enrollmentInfo":644,"targetDuration":4,"studyType":52,"phases":645,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":455,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":145},"100210617","phase-1-the-effect-of-oral-administration-of-9-cis-rich-powder-of-the-alga-dunaliella-bardawil-on-visual-functions-in-adolescent-patients-with-retinitis-pigmentosa-100210617","NCT02018692","The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa","The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Written informed consent to participate in the study.\n* Adolescent 12-18 years old.\n* Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa\n\nExclusion Criteria:\n\n* Currently a smoker\n* Current use of vitamin A\u002F β-carotene supplements\n* Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery\n* History of malignancy, excepting basal or squamous cell skin carcinoma\n* Females who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception\n* Uncontrolled hypertension, defined either as resting diastolic blood pressure \\>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \\>180 mmHg\n* History of alcohol abuse or drug abuse or both\n* Intention to engage in vigorous exercise or an aggressive diet regimen\n* Uncontrolled endocrine or metabolic disease\n* Participation in another investigational drug study within 4 weeks prior to enrolment\n* Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study\n* Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment","12 Years",{"count":523,"type":21},[182,156],"The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.",[26],"2025-09-30",{"date":650,"type":32},"2025-10-06",{"date":652,"type":21},"2026-03-01",{"date":654,"type":21},"2028-12-31",{"name":464,"class":465},{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":52,"phases":665,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":145},"100540671","phase-1-the-effects-of-disulfiram-antabuse-on-visual-acuity-in-patients-with-retinal-degeneration-100540671","NCT06319872","The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration","The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration","Inclusion Criteria:\n\n* All sexes, 18 years and older.\n* Participants must speak English, understand, and sign the informed consent document.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* In good general health as evidenced by medical history and with a clinical diagnosis of inherited retinal dystrophy or dry-AMD.\n* Best Corrected Visual Acuity (BCVA) of 20\u002F20 (with constriction or other defects of Goldmann visual field) to Light Perception in the better eye.\n* Intact inner nuclear layer, inner plexiform, and ganglion cell layer on macular SD-OCT.\n* Ability to take oral medication and be willing to adhere to the disulfiram regimen.\n* Patients must have the diagnosis of alcohol use disorder provided by an addiction specialist and be a candidate for therapeutic use of disulfiram for that condition.\n* Patients must agree to refrain from all alcohol consumption for 180 days.\n* Any female participant of childbearing potential must have a negative urine pregnancy test at screening.\n* Any female participant of childbearing potential must have (or have a partner who has) had a surgical sterilization (vasectomy, hysterectomy, or tubal ligation), be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for at least one week after disulfiram discontinuation. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring); intrauterine device; barrier methods (diaphragm, condom) with spermicide.\n\nExclusion Criteria:\n\n* A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., cardiovascular disease, hepatitis.\n* Individuals with a history of diabetes mellitus.\n* Individuals with a history of psychosis.\n* Individuals with hypothyroidism.\n* Individuals with hypersensitivity to thiuram derivatives causing rubber contact dermatitis.\n* Those on anticoagulant therapy or other medications that may be affected by disulfiram.\n* Ophthalmic conditions with independent effect upon visual function (e.g. diabetic retinopathy, glaucoma, cataract, vitreous hemorrhage, retinal detachment, active intraocular inflammation or active infectious ocular diseases, choroidal neovascularization).\n* Patients with No Light Perception (NLP) in both eyes.\n* History of major ocular surgery within the prior 6 months or major ocular surgery anticipated within the next 6 months following randomization.\n* Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis\n* Participation in an investigational trial that involves treatment with any drug within 30 days of randomization that has not received regulatory approval at the time of study entry. Note: study participants cannot receive another investigational drug while participating in this study.\n* Known allergy or hypersensitivity to any component of the study drug.\n* For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months.\n* Participants who expect to move out of the area of the clinical center during the 8 months of the study",{"count":664,"type":21},15,[182],"Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.",[668,506,58,26,59],"Alcohol Use Disorder","2025-09-23",{"date":671,"type":32},"2025-09-29",{"date":673,"type":32},"2025-05-19",{"date":675,"type":21},"2029-05-19",{"name":677,"class":39},"University of Rochester",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":685,"enrollmentInfo":686,"targetDuration":4,"studyType":52,"phases":688,"briefSummary":689,"conditions":690,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":145},"100504805","pilot-study-of-autna-i-100504805","NCT05853107","Pilot Study of AuTNA I","Pilot Study of AuTNA I (Au Nanoparticle-decorated TiO2 Nanowire Arrays, Retinal Prothesis) -a Safety and Efficacy Evaluation.","Inclusion Criteria:\n\n1. Age: 18-70 years of age.\n2. Clinically diagnosed as retinitis pigmentosa (one of the following two conditions):\n\n   ① typical triadfundus manifestations: \"osteoblastic\" pigmentation of retina, arterial stenosis, and waxy atrophy of optic disc.\n\n   ② typical fundus changes with both a and b, with or without c:\n   1. poor night vision before vision loss;\n   2. standard 5 ERG examination showing more severely damaged scotopic response than photopic, even non response\n   3. impaired peripheral visual field in perimetry (when the patient's vision permits).\n3. No or suspicious light perception in the eye for AuTNA I implantation.\n4. Intact inner retinal structure on OCT. No macular retinal or choroidal neovascularization.\n5. Voluntary to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Entities that might interfere with the functioning of AuTNA I, e.g. open ocular trauma, retinal detachment, glaucoma, severe uveitis, etc.\n2. Uncontrolled systemic diseases including hypertension (systolic blood pressure ≥160mmHg and\u002For diastolic blood pressure ≥100mmHg), diabetes (blood glucose ≥8.0mmol\u002FL with medication);\n3. Allergic constitution.\n4. Entities that might prevent the observation of the fundus, e.g. corneal opacity, etc.\n5. Ocular disease not suitable for undertaking the implantation surgery, e.g. corneal ulcers, etc.\n6. Habits of rubbing the eyes.\n7. Compromised liver function (ALT and AST 1.5 times over the normal limits), renal function (Cr 1.5 times over the normal limits), coagulation function (APTT 1.5 times over the normal limits).\n8. Pregnancy, lactating or planning to be pregnant within 6 months.\n9. History of epilepsy or serious psychiatric diseases.\n10. Other local or systemic diseases that may affect the vision.\n11. Participation in other clinical trials within 1 month before this study.\n12. Other conditions that the researcher found imporper to be included into this study.","70 Years",{"count":687,"type":21},7,[54],"The objective of the study is to evaluate:\n\n1. Safety of AuTNA I for subretinal implantation in patients with retinitis pigmentosa;\n2. Efficacy of AuTNA I for subretinal implantation in patients with retinitis pigmentosa.",[26],"2025-09-18",{"date":693,"type":32},"2025-09-19",{"date":695,"type":32},"2023-05-12",{"date":697,"type":21},"2026-02-28",{"name":699,"class":39},"Eye & ENT Hospital of Fudan University",{"id":701,"slug":702,"hasResults":12,"nctId":703,"briefTitle":704,"officialTitle":705,"acronym":4,"eligibilityCriteria":706,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":707,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":709,"conditions":710,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":719,"locationsCount":721},"100501467","study-of-best1-vitelliform-macular-dystrophy-100501467","NCT05809635","Study of BEST1 Vitelliform Macular Dystrophy","Natural History Study in Retinitis Pigmentosa Caused by Mutations in the BEST1 Gene","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Diagnosis of BEST1-associated VMD by study physician, who are trained retinal specialists in the university clinic Must be able to commit to 4 follow-up study visits (3 years)\n\nExclusion Criteria:\n\n* Systemic condition that prevents the participant from undergoing the exams",{"count":708,"type":21},52,"The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy.\n\nThe blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene.\n\nAs new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to:\n\n1. Report the natural history of retinal degeneration in participants with a clinical diagnosis of VMD with molecular confirmation of a pathogenic BEST1 mutation(s).\n2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials for the treatment of BESTROPHIN 1 VMD.\n3. Compare progression of the identified structural and functional measures between the two eyes to judge the suitability of the second untreated eye as a control for a future clinical trial involving unilateral treatment\n4. Identify well-defined patient populations for future clinical trials of investigative treatments for BEST1 VMD.",[711,26],"Best Vitelliform Macular Dystrophy","2025-07-28",{"date":714,"type":32},"2025-07-30",{"date":716,"type":32},"2021-03-30",{"date":718,"type":21},"2026-05-31",{"name":720,"class":39},"Columbia University",3]